Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative

Alzheimer's disease (AD) is characterized by specific and progressive reductions in fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the cerebral metabolic rate for glucose (CMRgl), some of which may precede the onset of symptoms. In this report, we describe twelve-month CMRgl declines in 69 probable AD patients, 154 amnestic mild cognitive impairment (MCI) patients, and 79 cognitively normal controls (NCs) from the AD Neuroimaging Initiative (ADNI) using statistical parametric mapping (SPM). We introduce the use of an empirically pre-defined statistical region-of-interest (sROI) to characterize CMRgl declines with optimal power and freedom from multiple comparisons, and we estimate the number of patients needed to characterize AD-slowing treatment effects in multi-center randomized clinical trials (RCTs). The AD and MCI groups each had significant twelve-month CMRgl declines bilaterally in posterior cingulate, medial and lateral parietal, medial and lateral temporal, frontal and occipital cortex, which were significantly greater than those in the NC group and correlated with measures of clinical decline. Using sROIs defined based on training sets of baseline and follow-up images to assess CMRgl declines in independent test sets from each patient group, we estimate the need for 66 AD patients or 217 MCI patients per treatment group to detect a 25% AD-slowing treatment effect in a twelve-month, multi-center RCT with 80% power and two-tailed alpha=0.05, roughly one-tenth the number of the patients needed to study MCI patients using clinical endpoints. Our findings support the use of FDG PET, brain-mapping algorithms and empirically pre-defined sROIs in RCTs of AD-slowing treatments.

[1]  Henrik Zetterberg,et al.  Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease , 2009, Neurobiology of Aging.

[2]  W. Jagust,et al.  Longitudinal studies of regional cerebral metabolism in Alzheimer's disease , 1988, Neurology.

[3]  C. Jack,et al.  Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor‐based morphometry , 2010, Human brain mapping.

[4]  Alan Carpenter,et al.  Relationship between regional amyloid levels and cognitive performance in healthy controls, MCI subjects, and patients with alzheimer's: Phase II results from a florpiramine F18 PET imaging study , 2009, Alzheimer's & Dementia.

[5]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[6]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[7]  L. Beckett,et al.  Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050 , 2001, Alzheimer disease and associated disorders.

[8]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Michael W. Weiner,et al.  O1-02-06: Twelve-month cerebral metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment: Preliminary findings from the Alzheimer's disease neuroimaging initiative (ADNI) , 2008, Alzheimer's & Dementia.

[10]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[11]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[13]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[14]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[16]  Nick C Fox,et al.  Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease , 1999, The Lancet.

[17]  et al.,et al.  Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2009, NeuroImage.

[18]  Satoshi Minoshima,et al.  Posterior cingulate cortex in Alzheimer's disease , 1994, The Lancet.

[19]  J. Haxby,et al.  Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. , 1990, Archives of neurology.

[20]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[21]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[22]  D. Wechsler.  Manual for the Wechsler Adult Intelligence Scale. , 1955 .

[23]  G. Alexander,et al.  Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .

[24]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[25]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[26]  K Herholz,et al.  Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. , 1994, Dementia.

[27]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[28]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[29]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[30]  Gunhild Waldemar,et al.  Rates of Cognitive Change in Alzheimer Disease: Observations Across a Decade of Placebo-controlled Clinical Trials With Donepezil , 2009, Alzheimer disease and associated disorders.

[31]  N. Foster,et al.  Alzheimer's disease , 1983, Neurology.

[32]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[33]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[34]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[35]  A. Convit,et al.  Reduced hippocampal metabolism in MCI and AD , 2005, Neurology.

[36]  Mayo Clinic,et al.  PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE , 2000 .

[37]  Holly Soares,et al.  Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele , 2004, Biological Psychiatry.

[38]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[39]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[40]  Bernard R. Rosner,et al.  Fundamentals of Biostatistics. , 1992 .

[41]  J. Trojanowski,et al.  Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics , 2007, Nature Reviews Drug Discovery.

[42]  Lars Farde,et al.  AZD2184: a radioligand for sensitive detection of β‐amyloid deposits , 2009, Journal of neurochemistry.

[43]  N. Foster,et al.  Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.

[44]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[45]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[46]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[47]  Norbert Schuff,et al.  Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects , 2009, NeuroImage.

[48]  B. Reisberg,et al.  Computed Tomography and Positron Emission Transaxial Tomography Evaluations of Normal Aging and Alzheimer's Disease , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[49]  G. Schellenberg,et al.  CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. , 2007, Neurology.

[50]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[51]  P. Tariot,et al.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. , 2010, Biomarkers in medicine.

[52]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[54]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[55]  Nick C Fox,et al.  Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.

[56]  Christer Halldin,et al.  Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  Rachel L. Mistur,et al.  FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[58]  Mark S. Cohen,et al.  Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.

[59]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[60]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[61]  Mark D'Esposito,et al.  Imaging the aging brain , 2009 .

[62]  Holly Soares,et al.  Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. , 2004, Biological psychiatry.

[63]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[64]  Eric M. Reiman,et al.  Brain Imaging in the Evaluation of Putative Alzheimer’s Disease-Slowing, Risk-Reducing and Prevention Therapies , 2009 .

[65]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[66]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.